Abstract 1057P
Background
TIS is an anti-programmed cell death protein 1 monoclonal antibody engineered to minimize FcγR binding. Primary results from this single-arm, multicenter, open-label, phase 2 study (NCT03736889) evaluating TIS in pts with MSI-H/dMMR solid tumors showed a clinically meaningful objective response rate (ORR). Here, we report updated analysis with longer follow-up.
Methods
Eligible adult participants had previously treated, locally advanced, unresectable/metastatic solid tumors with centrally confirmed MSI-H/dMMR, ≥1 measurable lesion (RECIST v1.1), and an ECOG performance status ≤1. Pts received TIS 200 mg intravenously once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was Independent Review Committee (IRC)-assessed ORR (RECIST v1.1). Secondary endpoints included overall survival (OS), IRC-assessed duration of response (DoR), progression-free survival (PFS), and disease control rate, and safety.
Results
Of 80 pts enrolled and treated in the study, 75 had measurable disease per IRC at baseline and were included in the efficacy-evaluable population. At data cutoff (Dec 5, 2022), median study follow-up was 28.9 months; minimum follow-up from last patient in to data cutoff was 28.1 months. Efficacy results are shown in the Table. ORR was 49.3%; median DoR, PFS, and OS were not reached. Treatment-emergent adverse events (TEAEs) ≥grade 3 occurred in 48 pts (60.0%); the most common was anemia, occurring in nine pts (11.3%). TEAEs leading to treatment discontinuation occurred in six pts (7.5%).
Conclusions
With a minimum of 28.1 months’ follow-up, TIS-treated pts with previously treated MSI-H/dMMR solid tumors demonstrated a higher ORR compared with previous analysis, and durable improvements in DoR, PFS, and OS, with no new safety signals. Table: 1057P
Tumor Response in the Efficacy-evaluable Population
All tumor types (N=75) | |
ORR, n (%) | 37 (49.3) |
95% CI | 37.6, 61.1 |
Best overall response, n (%) | |
Complete response | 10 (13.3) |
Partial response | 27 (36.0) |
mDoR, a mo (95% CI) | NR (NE, NE) |
24-month DoR rate, % (95% CI) | 97.0 (80.4, 99.6) |
mPFS, a mo (95% CI) | NR (7.5, NE) |
24-month PFS rate, % (95% CI) | 56.7 (44.1, 67.4) |
mOS, mo (95% CI) | NR (33.3, NE) |
24-month OS rate, % (95% CI) | 68.6 (56.6, 77.9) |
aIRC-assessed per RECIST v1.1 OS analysis is based on safety analysis population (N=80). CI, confidence interval; m, median; mo, months; NE, not estimable; NR, not reached.
Clinical trial identification
NCT03736889 (first posted November 9, 2018).
Editorial acknowledgement
This study was sponsored by BeiGene, Ltd. Medical writing support, under direction of the authors, was provided by Lorena Mejias Martinez, MSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
J. Li: Financial Interests, Principal Investigator: BeiGene. Y. Xu: Financial Interests, Principal Investigator: BeiGene. A. Zang: Financial Interests, Principal Investigator: BeiGene. Y. Gao: Financial Interests, Principal Investigator: BeiGene. Q. Gao: Financial Interests, Principal Investigator: BeiGene. Y. Zhang: Financial Interests, Principal Investigator: BeiGene. D. Wang: Financial Interests, Principal Investigator: BeiGene. H. Jiang: Financial Interests, Principal Investigator: BeiGene. J. Ying: Financial Interests, Principal Investigator: BeiGene. C. Shi: Financial Interests, Principal Investigator: BeiGene. Y. Deng: Financial Interests, Principal Investigator: BeiGene. J. Wang: Financial Interests, Principal Investigator: BeiGene. T. Liu: Financial Interests, Principal Investigator: BeiGene. Y. Huang: Financial Interests, Principal Investigator: BeiGene. M. Shi: Financial Interests, Full or part-time Employment: BeiGene. K. Wang: Financial Interests, Full or part-time Employment: BeiGene. H. Hu: Financial Interests, Full or part-time Employment: BeiGene. L. Shen: Financial Interests, Personal, Other, Consulting fees: Mingji biopharmaceutical, Haichuang pharmaceutical, Herbour biomed; Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, BI, Sanofi, Roche, SERVIER, AZ; Financial Interests, Institutional, Funding: Beijing Xiantong Biomedical Technology, Qilu Pharmaceutical, ZaiLab Pharmaceutical (Shanghai), Alphamab Oncology, Yaojie Ankang (Nanjing) Technology Co., Ltd., BeiGene, Ltd., Qiyu Biotechnology (Shanghai) Co., Ltd., BriSTAR immunotech; Financial Interests, Institutional, Local PI: Merck Healthcare KGaA, Roche; Financial Interests, Institutional, Trial Chair: Rongchang Pharmaceutical, Innovent, BeiGene, Ltd., Qilu Pharmaceutical, NovaRock Biotherapeutics Limited. All other authors have declared no conflicts of interest.
Resources from the same session
1070P - Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
Presenter: Tianqi Gu
Session: Poster session 19
1071P - Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
Presenter: Zimu Li
Session: Poster session 19
1072P - DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Presenter: Sina Fellermeier-Kopf
Session: Poster session 19
1073P - Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
Presenter: Ilya Tsimafeyeu
Session: Poster session 19
1074TiP - A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Presenter: Martin Gutierrez
Session: Poster session 19
1075TiP - A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Presenter: Ecaterina Dumbrava
Session: Poster session 19
1076TiP - First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Presenter: Sunil Babu
Session: Poster session 19
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19
1078TiP - Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 19